Supreme Court Questions Medicine Pricing Explained: MRP vs Retailer Price, the 30% Cancer-Drug Cap, and What the Reserved Verdict Could Change
Key Takeaways
- On 27 October 2026 the Supreme Court bench of Justices Vikram Nath and Sandeep Mehta heard medicine pricing petitions and reserved its order; no verdict has been delivered yet.
- The bench questioned the gap between medicine MRPs and retailer prices, citing a saline drip line costing about Rs 15 but billed at about Rs 250, and a chemotherapy injection available at Rs 11,000 but charged at Rs 1,30,000.
- The Centre said India has among the world's lowest medicine prices and that the whole ecosystem should not be tightly controlled; the bench said low prices must be weighed against low per capita income.
- The Centre's 30 percent trade margin cap on anti-cancer drugs is expected to save patients about Rs 2,500 crore a year, but the bench asked why action came only now and why other medicines are not covered.
- Hospitals argued their own pharmacies ensure quality and availability; the bench rejected excessive medicine mark-ups as a way to recover hospital running costs.
What happened in the Supreme Court on 27 October 2026
On Tuesday, 27 October 2026, a Supreme Court bench of Justices Vikram Nath and Sandeep Mehta heard public interest petitions about medicine prices in India and then reserved its order, meaning the court has finished hearing arguments for now and will deliver its decision later. The bench also directed all parties to file their written submissions. No final verdict has been given yet, so nothing in this article should be read as a new rule that is already in force.
The hearing turned on a simple but uncomfortable question: why is there such a large gap between the maximum retail price (MRP) printed on a medicine and the price at which retailers and hospitals obtain it? The bench asked, in sharp terms, why the entire system appeared to be working to help pharmaceutical manufacturers, and whether the government was allowing opaque pricing to continue unchecked. At one point the bench described the National Pharmaceutical Pricing Authority (NPPA), the regulator that oversees drug prices, as appearing to be a totally defunct body, and asked whether the system should be allowed to run amok in favour of manufacturers.
The Centre, represented by Additional Solicitor General Aishwarya Bhati, defended its approach. It said government policy is that the entire pharmaceutical ecosystem is not to be tightly controlled, and that medicine prices in India are among the lowest in the world. The bench pushed back on that framing, observing that a discussion about low prices would also have to take account of low per capita income and other factors. In other words, a price that looks low in absolute terms can still be a heavy burden for a patient paying out of pocket.
The two examples that framed the hearing
Two examples cited in court explain why the judges treated this as a question about patients' lives rather than ordinary commerce. The first concerned a saline drip line: according to the account placed before the court, a retailer pays around Rs 15 for the item, while a patient can be billed around Rs 250 for it. The bench asked why the Drug Price Control Order (DPCO), the regulatory framework for controlling drug prices, exists at all if such mark-ups continue. It observed that this was happening under the government's own eyes.
The second example was more personal, and the bench returned to it more than once. A medical distributor whose wife was being treated for cancer at a prominent private hospital told the hospital that he himself could obtain a chemotherapy injection at a dealer price of Rs 11,000. According to the account before the court, the hospital refused to administer the injection he offered and instead charged Rs 1,30,000 for the same injection. The bench asked the Centre to justify the difference: where does the money go, and what justifies calling that difference a legitimate margin rather than an excessive mark-up?
These are examples raised in court proceedings, not findings about every hospital or every medicine. They matter because they illustrate the core complaint in the petitions: the price a patient finally pays can bear little visible relationship to the price at which the medicine changes hands earlier in the supply chain, and the patient, unlike a dealer or a hospital, usually has no way to negotiate or even to see that chain.
MRP, trade margin and the DPCO: the terms that matter
To follow the case, three terms are worth separating clearly. The MRP is the maximum price printed on the pack, the ceiling at which the medicine may be sold to a consumer. The trade margin is the difference retained along the supply chain between what an intermediary pays and the MRP, covering distributors, wholesalers, retailers and, in hospital settings, the hospital pharmacy. A trade margin cap limits that retained share to a fixed percentage of the MRP, so that a larger part of any price reduction reaches the patient rather than being absorbed on the way.
The DPCO is the order under which the government controls the prices of certain medicines, and the NPPA is the authority that implements price regulation, including fixing ceiling prices for scheduled formulations. The petitioners' argument, as reflected in the hearing, is that this framework is not doing enough work in practice: if MRPs are set high and margins are left uncapped for many medicines, then even a formally regulated system can leave patients paying far more than the underlying supply price would suggest.
The Centre's counter-argument is about balance. It says the government is trying to balance the interests of manufacturers, distributors, retailers and patients, and to avoid a regime so tight that it discourages supply or availability. That tension, between keeping medicines available and keeping them affordable, is the real policy question behind the courtroom exchanges. A cap that is too low could, in theory, make some suppliers withdraw; a system with no effective cap leaves patients exposed to whatever margin the chain chooses to take.
The 30 percent cap on anti-cancer drugs
The most concrete step discussed in court concerns anti-cancer medicines. The Centre told the court that it has decided to cap the trade margin on anti-cancer drugs at 30 percent of the MRP, and that this step is expected to save patients approximately Rs 2,500 crore a year. In an affidavit, the Department of Pharmaceuticals said the measure could reduce the MRP of cancer medicines by 20 to 70 percent depending on the drug, while retaining reasonable margins for distributors and retailers.
The bench was not satisfied with that answer on its own. At an earlier hearing on 12 October, it had described the Centre's response on the 30 percent cap as hardly anything to be happy about, and asked why the government could not cap trade margins on other medicines as well. On 27 October it pressed the same point from a different angle: why had the government acted only now, after years of silence on the issue? The bench told the Centre that it was dealing with matters concerning people's lives and should not treat the issue as a business matter or force the court to ask harsh questions.
The Centre pointed to a precedent. In 2019, the NPPA imposed a 30 percent trade margin cap on 42 selected non-scheduled anti-cancer medicines. According to the Centre, that step reduced the MRP of 526 brands and generated estimated annual savings of around Rs 984 crore for patients. Supporters of the new cap will read that history as evidence that a margin cap can lower prices without collapsing supply. Critics, and the bench itself, will ask why a similar approach has not been extended more widely, and why it took a court case to produce the latest step.
What the hospitals argued, and why the bench rejected it
Private hospitals, represented by senior advocate Mukul Rohatgi, argued that hospitals need to procure medicines through their own pharmacies to ensure the availability and quality of the drugs administered to patients. Medicines bought in the open market, the argument went, cannot always be trusted to be genuine, and hospitals must maintain infrastructure and facilities round the clock. Rohatgi also contended that reducing medicine prices would not necessarily bring down the overall cost of treatment, because hospitals would have to recover their operational expenses through other charges.
The bench rejected that justification in unusually blunt language. It observed that a hospital can survive through other means, but not through excessive mark-ups on medicines, and asked why a medicine should be quoted at 100 or 200 times its underlying price when the hospital already charges for its services. The point is not that hospitals should run at a loss; it is that medicine pricing should not be the hidden channel through which treatment costs are recovered, especially when patients cannot judge whether a medicine charge is fair.
This exchange also touches on a wider problem with hospital billing. When a patient is admitted, they rarely choose each medicine or consumable separately, and they cannot easily compare the hospital's price with a pharmacy price in the middle of treatment. That information gap is precisely what price regulation is meant to correct, and it is why the court focused on transparency and margins rather than only on the final bill.
Background: why medicine pricing reaches the Supreme Court at all
Medicine pricing disputes reach the Supreme Court because the petitions raise a mix of constitutional and regulatory questions: whether the existing framework protects patients effectively, whether the regulator is enforcing the rules it already has, and whether the government should be directed to act where it has not. The petitions before the bench on 27 October covered the regulation of medicine prices, generic medicines, medical devices and prescription practices, so the case is broader than any single drug or any single hospital bill.
The background also includes the Ayushman Bharat scheme, which the bench mentioned during the hearing. Government-backed health schemes reimburse treatment only up to a specified limit, and the bench observed that any expenditure beyond that limit ultimately has to be borne by patients themselves. That makes medicine mark-ups doubly painful for insured patients: the scheme may cover part of the bill, but an inflated medicine charge can still push the total beyond the covered amount and leave the family to pay the difference.
Generic medicines are part of the same background. A generic medicine contains the same active ingredient as a branded medicine and is usually cheaper, but patients often do not know whether a cheaper equivalent exists, whether their doctor will prescribe it, or whether the pharmacy will offer it. The petitions' interest in prescription practices reflects that concern: pricing reform alone may not help if prescribing and dispensing habits keep steering patients toward the most expensive option.
What could happen next, and what it would mean for patients
Because the court has reserved its order, the honest answer to what happens next is that it depends on the verdict, which has not yet been delivered. Several outcomes are possible, and patients should not assume any of them until the order is published. The court could issue directions to strengthen NPPA enforcement, require clearer disclosure of trade margins and discounts, or order broader regulatory reforms affecting how hospitals, distributors and retailers set final prices. It could also accept the Centre's steps, including the 30 percent anti-cancer cap, as sufficient for now, or it could set a timetable for further action.
If the court directs wider margin caps, the most direct effect would be on the gap between supply prices and MRPs: medicines whose margins are capped should see lower MRPs, and patients paying out of pocket should see lower bills for those medicines. If the court instead focuses on disclosure, patients and regulators would at least be able to see where the money goes, which makes future regulation easier to design and harder to evade. If the court accepts the Centre's position, the immediate change would be limited to anti-cancer medicines, and the wider debate about other medicines would return to the government and Parliament rather than the courtroom.
For ordinary patients, the practical lesson does not depend on the verdict. It is worth asking for an itemised bill, checking whether a prescribed medicine has a cheaper generic equivalent, and comparing the hospital pharmacy price with a nearby retail pharmacy price where treatment allows it. None of that replaces regulation, and none of it helps a patient in an emergency, but it is the small amount of leverage patients currently have in a system where prices are often set far from their view.
Conclusion
The 27 October hearing did not settle medicine pricing in India, but it made the stakes unusually clear. On one side is a government that says prices are already among the world's lowest and that the ecosystem should not be tightly controlled. On the other side is a court that looked at a Rs 15 item billed at Rs 250 and a Rs 11,000 injection charged at Rs 1,30,000, and asked why patients should bear the cost of a system that allows such gaps. The 30 percent cap on anti-cancer drug margins, with its projected Rs 2,500 crore annual saving, is a real step, but the bench's questions show why it is being treated as a beginning rather than an answer.
The reserved verdict will decide whether that beginning becomes a broader reform. Until the order is delivered, the most accurate summary is this: the court has heard the arguments, it has expressed serious concern about the regulator and about hospital mark-ups, and it has kept the question open. Patients, hospitals, manufacturers and the government are all waiting on the same document, and its reasoning will matter as much as its directions, because it will define how far the law is willing to go to make medicine prices match the prices patients can actually afford.